---
schema_version: "secwatch.filing_event.v1"
accession: "0000898432-23-000117"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:16:06.183989+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bellevue Life Sciences Acquisition Corp. closes IPO and full over-allotment, raising $69M

## Summary
- IPO of 6M units at $10/unit closed Feb 14, 2023; over-allotment of 900K units exercised in full, total 6.9M units.
- Gross proceeds of $69M from IPO and over-allotment; $70.2M placed in trust account including private placement.
- Appointed five independent directors: Dr. Steven G. Reed (Chairman), Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, Mr. Jin Whan Park.
- Units trade on Nasdaq under BLACU; common, warrants, rights under BLAC, BLACW, BLACR.

## SEC filing metadata
- accession: 0000898432-23-000117
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000898432-23-000117
- JSON: https://secwatch.observer/filing/0000898432-23-000117.json
- Plain text: https://secwatch.observer/filing/0000898432-23-000117.txt

## Key facts
- Executive change
  Dr. Steven G. Reed was appointed as Chairman of the Board at OSR Holdings, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm
- Executive change
  Dr. Rad Roberts was appointed as Director at OSR Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm
- Executive change
  Dr. In Chul Chung was appointed as Director at OSR Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm
- Executive change
  Mr. Jin Whan Park was appointed as Director at OSR Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm
- Executive change
  Mr. Hosun Euh was appointed as Director at OSR Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.